

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-04 Medicare Claims Processing	Centers for Medicare & Medicaid Services (CMS)
Transmittal 12653	Date: May 23, 2024
	Change Request 13620

SUBJECT: Healthcare Common Procedure Coding System (HCPCS) Codes Subject to and Excluded from Clinical Laboratory Improvement Amendments (CLIA) Edits

I. SUMMARY OF CHANGES: The purpose of this Change Request (CR) is to inform contractors about the new HCPCS codes for 2024 that are subject to and excluded from CLIA edits. This Recurring Update Notification applies to Chapter 16, section 70.9.

EFFECTIVE DATE: October 1, 2024

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: October 7, 2024

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-Only One Per Row.

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
N/A	N/A

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:

Recurring Update Notification

Attachment - Recurring Update Notification

Pub. 100-04	Transmittal: 12653	Date: May 23, 2024	Change Request: 13620
-------------	--------------------	--------------------	-----------------------

SUBJECT: Healthcare Common Procedure Coding System (HCPCS) Codes Subject to and Excluded from Clinical Laboratory Improvement Amendments (CLIA) Edits

EFFECTIVE DATE: October 1, 2024

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: October 7, 2024

I. GENERAL INFORMATION

A. Background: The purpose of this Change Request (CR) is to inform contractors about the new HCPCS codes for 2024 that are subject to and excluded from CLIA edits. This Recurring Update Notification applies to Chapter 16, section 70.9.

The Clinical Laboratory Improvement Amendments (CLIA) regulations require a facility to be appropriately certified for each test performed. To ensure that Medicare & Medicaid only pay for laboratory tests performed in certified facilities, each claim for a HCPCS code that is considered a CLIA laboratory test is currently edited at the CLIA certificate level.

The HCPCS codes that are considered a laboratory test under CLIA change each year. Contractors need to be informed about the new HCPCS codes that are both subject to CLIA edits and excluded from CLIA edits.

The following HCPCS codes were discontinued on October 1, 2023:

- 0357U - Artificial intelligence (AI)-enabled evaluation of 142 pairs of glycopeptide and product fragments in plasma to determine benefit from immunotherapy agents for skin cancer;
- 0386U - Testing for risk of Barrett's esophagus progression to esophageal cancer; and
- 0397U - Cell-free DNA testing in plasma evaluating of at least 109 genes in non-small cell lung cancer.

The following HCPCS codes were discontinued on April 1, 2024:

- 0354U - Human papilloma virus (HPV), high-risk types (ie, 16, 18, 31, 33, 45, 52 and 58) qualitative mRNA expression of E6/E7 by quantitative polymerase chain reaction (qPCR);
- 0416U - Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine.

The following HCPCS codes were discontinued on July 1, 2024:

- 0204U - Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected; and
- 0353U - Infectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detected.

The HCPCS codes that follow are all subject to CLIA edits. These lists do not include new HCPCS codes for waived tests or provider-performed microscopy procedures. All of these HCPCS codes require a facility to have either a CLIA certificate of registration (certificate type code 9), a CLIA certificate of compliance (certificate type code 1), or a CLIA certificate of accreditation (certificate type code 3). A facility without a valid, current, CLIA certificate, with a current CLIA certificate of waiver (certificate type code 2) or with a current CLIA certificate for provider-performed microscopy procedures (certificate type code 4) must not be permitted to be paid for these tests, unless a facility with a current CLIA certificate of waiver (certificate type code 2) or CLIA certificate for provider-performed microscopy procedures (certificate type code 4) bills the appropriate HCPCS service code with a QW modifier.

The HCPCS codes listed below were added on April 1, 2023, and are subject to CLIA edits.

0364U - Genomic sequence testing for presence or absence of cancer cells after treatment in leukemia or lymphoma;

0365U - Test for 10 protein biomarkers for bladder cancer;

0366U - Test for 10 protein biomarkers for recurrent bladder cancer;

0367U - Test for 10 protein biomarkers for rapid recurrent, recurrent, or persistent bladder cancer after bladder surgery to remove a tumor;

0368U - Test for risk of colorectal cancer;

0369U - Test for 31 stomach and intestinal pathogens and identification of 21 antibiotic resistant genes;

0370U - Test for 34 surgical wound microorganisms and identification of 21 antibiotic resistant genes;

0371U - Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal organism;

0372U - Test for genitourinary pathogen antibiotic-resistance genes;

0373U - Test for 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes associated with respiratory infection;

0374U - Test for 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic-resistance genes;

0375U - Test for proteins to determine risk for ovarian cancer;

0376U - Test to determine potential risk of prostate cancer spread and mortality;

0377U - Test of lipoprotein profile in cardiovascular disease;

0378U - Test for RFC1 (replication factor C subunit 1) in neurological conditions;

0379U - Genomic testing for solid organ cancer;

0380U - Test for adverse drug reactions and drug response;

0381U - Test for monitoring maple syrup urine disease;

0382U - Test for monitoring hyperphenylalaninemia;

0383U - Test for monitoring tyrosinemia type I;

0384U - Test for predictive risk of progression of high-stage kidney disease; and

0385U - Testing for risk of developing diabetic kidney disease.

The HCPCS codes listed below were added on July 1, 2023, and are subject to CLIA edits.

0387U - Tissue evaluation for proteins to report risk of skin cancer progression;

0388U - Next-generation sequencing in plasma of 37 cancer-related genes, with report for alteration detection in non-small cell lung cancer;

0389U - Reverse transcription polymerase chain reaction (RT-qPCR) testing of blood for proteins, reported as a risk score for Kawasaki disease;

0390U - Immunoassay of serum for proteins, reported as a risk score for preeclampsia;

0391U - DNA and RNA next-generation sequencing of tissue for 437 genes with algorithm quantifying immunotherapy response score;

0392U - Evaluation of gene-drug interactions for 16 genes reported as impact of gene-drug interaction for each drug for depression, anxiety, attention deficit disorder;

0393U - Detection of protein by seed amplification assay for neurological disorders;

0394U - Testing of plasma or serum for 16 perfluoroalkyl substances (PFAS) compounds;

0395U - Multi-omics testing of plasma reported as risk of malignancy for lung nodules in early-stage lung cancer;

0396U - Microarray testing of embryonic tissue for 300000 DNA single-nucleotide polymorphisms (SNPs), reported as a probability for single-gene germline conditions in pre-implantation genetic testing;

0398U - DNA methylation analysis using polymerase chain reaction testing of tissue for genes specific to Barrett esophagus, reported as a risk score for progression to high grade dysplasia or cancer;

0399U - Enzyme-linked assay detection in serum of IgG-binding antibody and blocking autoantibodies, using a functional blocking assay for IgG or IgM reported as positive or not detected in cerebral folate deficiency;

0400U - Next-generation sequencing of DNA for 145 genes reported as carrier positive or negative in expanded carrier screening; and

0401U - Targeted variant genotyping using blood, saliva, or buccal swab of 9 genes for coronary heart disease reported as a risk score for a coronary event.

The HCPCS codes listed below were added on October 1, 2023, are subject to CLIA edits.

0402U - Detection of organisms causing sexually transmitted infection by multiplex amplified probe technique;

0403U - mRNA expression profiling of 18 genes to detect potential risk of prostate cancer;

- 0404U - Analysis of serum using immunoassay technique for thymidine kinase activity in breast cancer;
- 0405U - Sequencing of methylation haplotype block markers in plasma in pancreatic cancer;
- 0406U - Flow cytometry detection of 5 markers in sputum to evaluate potential for lung cancer;
- 0407U - Measurement of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) to evaluate risk of progressive decline in kidney function in diabetic chronic kidney disease;
- 0408U - Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by bulk acoustic wave biosensor immunoassay;
- 0409U - Next-generation sequencing of DNA (80 genes) and RNA (39 genes) in plasma showing mutations and clinical actionability in solid tumor cancers;
- 0410U - Whole genome sequencing of DNA in whole blood or plasma to detect pancreatic cancer;
- 0411U - Genomic analysis of 15 genes to evaluate for psychiatric disorders;
- 0412U - Measurement of AB42/40 ratio in plasma to evaluation for brain amyloid pathology;
- 0413U - Optical genome mapping of DNA in blood or bone marrow for changes in copy number alterations, aneuploidy, and balanced/complex structural rearrangements in blood and lymphatic system abnormal tissue;
- 0414U - Whole slide imaging analysis for 8 genes for evaluation of lung cancer;
- 0415U - Test of biomarkers in blood combined with patient factors to determine a 5-year risk score for acute coronary syndrome;
- 0417U - Whole genome sequence analysis of 335 nuclear genes in blood or saliva for detection of abnormalities associated with rare constitutional/heritable diseases;
- 0418U - Image analysis of breast cancer cell specimen with autonomous assessment; and
- 0419U - Genomic sequence analysis of 13 genes in saliva for evolution of psychiatric disorders.

The HCPCS codes listed below were added on January 1, 2024, are subject to CLIA edits.

- 0420U - Oncology (urothelial), mrna expression profiling by real-time quantitative pcr of mdk, hoxa13, cdc2, igfbp5, and cxcr2 in combination with droplet digital pcr (ddpcr) analysis of 6 single-nucleotide polymorphisms (snps) genes tert and fgfr3, urine, algorithm reported as a risk score for urothelial carcinoma;
- 0421U - Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 rna markers (gapdh, smad4, acyl1, areg, cdh1, kras, tnfrsf10b, egl2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk;
- 0422U - Oncology (pan-solid tumor), analysis of dna biomarker response to anti-cancer therapy using cell-free circulating dna, biomarker comparison to a previous baseline pre-treatment cell-free circulating dna analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate;

0423U - Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition;

0424U - Oncology (prostate), exosome-based analysis of 53 small noncoding rnas (snrnas) by quantitative reverse transcription polymerase chain reaction (rt-qpcr), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer;

0425U - Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings);

0426U - Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis;

0427U - Monocyte distribution width, whole blood (list separately in addition to code for primary procedure);

0428U - Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor dna (ctdna) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden;

0429U - Human papillomavirus (hpv), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68);

0430U - Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative;

0431U - Glycine receptor alpha 1 igg, serum or cerebrospinal fluid (csf), live cell-binding assay (lcba), qualitative;

0432U - Kelch-like protein 11 (klhl11) antibody, serum or cerebrospinal fluid (csf), cell-binding assay, qualitative;

0433U - Oncology (prostate), 5 dna regulatory markers by quantitative pcr, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer;

0434U - Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes;

0435U - Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (cscs), from cultured cscs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations;

0436U - Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy;

0437U - Psychiatry (anxiety disorders), mrna, gene expression profiling by rna sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score;

0438U - Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of cyp2d6, including reported phenotypes and impacted gene-drug interactions;

81457 - Genomic sequence analysis panel of DNA for microsatellite instability in solid organ abnormal growth of tissue;

81458 - Genomic sequence analysis panel of DNA for microsatellite instability and copy number of variants in solid organ abnormal growth of tissue;

81459 - Genomic sequence analysis panel of DNA or combined DNA and RNA for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue;

81462 - Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants and rearrangements in solid organ abnormal growth of tissue;

81463 - Genomic sequence analysis of DNA in plasma for copy number variants and microsatellite instability in solid organ abnormal growth of tissue;

81464 - Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue;

81517 - Test for detecting 3 biomarkers associated with risk for liver disease;

82166 - Test for anti-mullerian hormone;

86041 - Test for acetylcholine receptor binding antibody;

86042 - Test for acetylcholine receptor blocking antibody;

86043 - Test for acetylcholine receptor modulating antibody; and

86366 - Test for muscle-specific kinase antibody.

The HCPCS codes listed below were added on April 1, 2024, are subject to CLIA edits.

0439U - Crd chd dna alys 5 snp 3 dna;

0440U - Crd chd dna alys 10 snp 6dna;

0441U - Nfct ds bct fngl/viral semiq;

0442U - Nfct ds respir nfctj mxachar_error

0443U - Neurflmnt lt chn ultrasens ia;

0444U - Onc sld orgn neo tgsap 361;

0445U - Abeta42 & ptau181 eclia csf;

0446U - Ai ds sle alys 10 cytokine;

0447U - Ai ds sle alys 11 cytokine;

0448U - Onc lng&cln ca dna qual ngs; and

0449U - Car scr sev inh cond 5 genes.

The HCPCS codes listed below were added on July 1, 2024, are subject to CLIA edits.

0450U - ONC MM LC-MS/MS MONOC P-PRTN;
0451U - ONC MM LC-MS/MS PEP ION QUAN;
0452U - ONC BLDR MTHYL PENK LTE-QMSP;
0453U - ONC CLRCT CA CFDNA QPCR ASY;
0454U - RARE DS ID OPT GENOME MAPG;
0455U - NFCT AGT STI MULT AMP PRB UR;
0456U - AI RA NGS 19 GENES ANTI-CCP;
0457U - PFAS 9 CMPND LCMS/MS PLS/SR;
0458U - ONC BRST CA S100 A8&A9 ELISA;
0459U - ABETA42 & TTAU ECLIA CSF;
0460U - ONC WHL BLD/BUCC RTPCR 24GEN;
0461U - ONC RXGENOM ALYS RTPCR 24GEN;
0462U - MELATONIN LVL TST SLP STD7/9;
0463U - ONC CRVX MRNA GENXPRSN 14BMK;
0464U - ONC CLRCT SCR QRTSA DNA MRK;
0465U - ONC URTHL CARC DNA QMSP 2GEN;
0466U - CRD CAD DNA GWAS 564856 SNP;
0467U - ONC BLDR DNA NGS 60GENchar_error
0468U - HEP NASH MIR34A5P A2M YKL40;
0469U - RARE DS WHL GEN SEQ FTL SAMP;
0470U - ONC OROP DETCJ MRD 8 DNA HPV;
0471U - ONC CLRC CA 35 VRN KRASchar_error
0472U - CA VI PSP&SP1 ANTB SJÖGREN;
0473U - ONC SLD TUM BLD/SLV 648 GENE;
0474U - HERED PAN CA GSAP 88GENE NGS; and
0475U - HERED PRST8 CA GSAP 23 GENES.

“***NOTE*** This instruction is NOT intended to rescind/replace any previous instructions indicating that a laboratory with a valid CLIA certificate of waiver or CLIA certificate for provider-performed microscopy procedures be allowed to bill the above codes with a QW modifier.

This Recurring Update Notification applies to Chapter 16, Section 70.9.

B. Policy: The CLIA regulations require a facility to be appropriately certified for each test performed. To ensure that Medicare and Medicaid only pay for laboratory tests in a facility with a valid, current CLIA certificate, laboratory claims are currently edited at the CLIA certificate level.

II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	
13620.1	Contractors shall apply CLIA edits to the HCPCS codes mentioned above as subject to CLIA edits.		X						X	
13620.2	Contractors shall deny payment for a claim submitted with the HCPCS codes mentioned above as subject to CLIA edits to a provider without valid current CLIA certificate, with a CLIA certificate of waiver (certificate type code 2) (when billed <i>without</i> the ‘QW’ modifier), or with a CLIA certificate for provider-performed microscopy procedures (certificate type code 4) (when billed <i>without</i> the ‘QW’ modifier).		X							
13620.3	Contractors shall return a claim as unprocessable if a CLIA number is not submitted on claims by providers for the HCPCS mentioned above as subject to CLIA edits.		X							
13620.4	Contractors need not search their files to either retract payment for claims already paid or to retroactively pay claims. However, contractors shall adjust claims brought to their attention.		X							

Number	Requirement	Responsibility								
		A/B MAC			DME MAC	Shared-System Maintainers				Other
		A	B	HHH		FISS	MCS	VMS	CWF	

III. PROVIDER EDUCATION TABLE

Number	Requirement	Responsibility				
		A/B MAC			DME MAC	CEDI
		A	B	HHH		
13620.5	Medicare Learning Network® (MLN): CMS will develop and release national provider education content and market it through the MLN Connects® newsletter shortly after we issue the CR. MACs shall link to relevant information on your website and follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1 for distributing the newsletter to providers. When you follow this manual section, you don't need to separately track and report MLN content releases. You may supplement with your local educational content after we release the newsletter.		X			

IV. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements:

"Should" denotes a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:
	N/A

Section B: All other recommendations and supporting information: N/A

V. CONTACTS

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VI. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question

and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0